NewsRoom Articles - Page 144 of 228

FridayDec 17, 2021 2:00 pm

Study Finds CBD Cigarettes Decrease Use of Antipsychotic Medications

CBD cigarettes are cigarettes manufactured from hemp instead of tobacco. The cigarettes contain CBD and a small amount of THC. CBD is a nonpsychoactive compound found in cannabis while THC is the psychoactive compound that induces a high. Data from a new trial has found that the use of CBD cigarettes is linked to a decrease in patients’ use of antipsychotic drugs. The cigarettes’ effects usually last two to three hours and take between a few seconds and some minutes to set in. This mode of consumption makes it the fastest way to feel CBD’s effects. The placebo-controlled trial was…

ThursdayDec 16, 2021 12:00 pm

Yale Studies Could Lead to Improved Treatment of Cancer

Two new studies led by researchers from Yale have discovered new information about the ALK receptor (anaplastic lymphoma kinase molecule) and the role it plays in cancer formation. The studies have made progress in determining ALK’s structure status as a receptor protein. Their findings were published in “Nature.” The codirector of the Cancer Biology Institute, Joseph Schlessinger, is a senior author of one of the studies. Yale School of Medicine assistant professor of pharmacology Daryl Klein is the senior author of the second study. A postdoctoral associate in Klein’s laboratory, Tongqing Li, stated that ALK was one of the receptor…

WednesdayDec 15, 2021 11:06 am

Drug Addiction: The US Searches for Novel Ways to Prevent Overdoses

Opioids are a class of drugs made from the opium poppy plant. These drugs work in the brain to produce various effects, including pain relief. Opioids are usually given as prescription medications to treat moderate to severe pain. However, long-term use of the drugs increases an individual’s dependence and tolerance, which results in higher and more frequent doses and sometimes addiction. In 2019, almost 50,000 individuals in the United States died from opioid-related overdoses. This number has steadily increased since then, with the most recent figures showing that 100,000 people have died because of overdoses associated with fentanyl in the…

TuesdayDec 14, 2021 11:32 am

Review Finds Aerobic Exercise Benefits Fibromyalgia Patients

A review published in the “Cochrane Library” stated that aerobic exercise may be beneficial to patients suffering from fibromyalgia. Aerobic exercises such as swimming and walking are known to improve cardiovascular conditioning, in addition to other benefits. These include helping control weight and blood sugar, lowering an individual’s blood pressure, improving circulation and strengthening the heart. The systematic literature review was conducted by researchers from the Norwegian Institute of Public Health in Oslo, led by Julia Bidonde. Fibromyalgia is a disorder characterized by musculoskeletal pain that is normally accompanied by mood and memory issues, sleep issues and fatigue. Experts believe…

MondayDec 13, 2021 9:56 am

Pandemic Exposes Extent of Kids’ Mental Health Issues

The coronavirus pandemic has not only affected economies around the globe but also impacted the mental health of both grown-ups and children significantly. Behavioral disorders, anxiety and depression are among the leading causes of disability and illness among adolescents. Data from the World Health Organization (“WHO”) shows that one in every seven children between the ages of 10 to 19 experiences a mental disorder, which makes up about 13% of the worldwide burden of illness. Adolescents with mental health issues are especially vulnerable to risk-taking behaviors, educational difficulties, stigma, discrimination and social exclusion. Harvard professor Karestan Koenen notes that the…

FridayDec 10, 2021 12:58 pm

Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) Discusses Psychedelics Research, Life Sciences Focus, at Key Industry Conferences

MINDCURE President and CEO Kelsey Ramsden will participate in, and has already attended multiple industry conferences throughout December Participation in #CanndoraConnect: Women in Psychedelics Conference focused on exploring job opportunities in psychedelics Company remains focused on promoting healing and improving mental health via digital therapeutics technology and psychedelic compounds research Company reports that 971 million people worldwide suffer from a mental disorder. As of 2019, MINDCURE calculates that 12,472 registered mental health facilities treatment facilities could benefit from the company’s proprietary digital therapeutics technology, iSTRYM The global digital therapeutics market is valued at $3.4 billion and is projected to reach…

FridayDec 10, 2021 9:33 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) New Patent Application Offering Improved Delivery Control, Enhanced Shelf Stability, of Psilocin

The full patent application covers multiple families of psilocin analogs. Psilocin is the active metabolite of psilocybin In addition to improving delivery control, the company’s dermal application route can potentially eliminate undesirable side effects such as nausea Mydecine appoints Dr. Saeid Babaei, PhD, as an independent board member. The appointment can help advance the company’s NASDAQ listing efforts, bringing decades of experience in biotech development and licensing and strategic advancements Company intends to uplist to NASDAQ in Q1 2022 Improving delivery control and shelf stabilization of psilocybin’s active metabolite psilocin, two critical aspects for use in medical settings, is the…

FridayDec 10, 2021 9:30 am

Study Finds Type 2 Diabetes More Prevalent in Those with Psychiatric Disorders

Diabetes is a common disease, with figures showing that about 6% of the global population is afflicted by the ailment. Since 1990, rates of the disease have been increasing, with estimates showing that this trend is expected to continue for at least two more decades. Now new research has found that type 2 diabetes is more common in individuals with psychiatric disorder, in comparison with other people. The research was carried out by a team of researchers from the University of Southern Denmark, led by Nanna Lindekilde of the school’s psychology department. Its findings were reported in “Diabetologia.” Psychiatric disorders…

ThursdayDec 09, 2021 1:36 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Set to Proceed with its Phase 2a Fibromyalgia Study Following FDA Confirmation

Tryp just announced FDA confirmation for its IND application filed in November 2021 The confirmation allows the company to proceed with its Phase 2a study on the effectiveness of psilocybin-assisted therapy among patients with fibromyalgia This clinical study will be one of the first to evaluate synthetic psilocybin for fibromyalgia in a Phase 2 study It is set to commence in 2022 and will involve 20 fibromyalgia patients Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) just announced that it would be proceeding with its upcoming Phase 2a fibromyalgia study, following a confirmation from the U.S. Food and Drug Administration (“FDA”) (https://ibn.fm/C20cT).…

ThursdayDec 09, 2021 1:26 pm

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) to Fund, Support First-Ever Psychedelic Treatment Clinic at Manhattan Hospital

Company receives grant to fund clinic for marginalized, underserved NYC communities New clinic will offer psychedelic treatment with no out-of-pocket cost for individuals unable to afford the service Program’s clinicians will receive specialized training Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing psychedelics to therapeutics, is marking key milestones in its mission to revolutionize mental healthcare. The company recently received a grant for the first-ever psychedelic treatment clinic at Lenox Hill Hospital (https://ibn.fm/zyerA). Part of Northwell Health, the largest healthcare system in New York State, Lenox Hill Hospital serves marginalized and underserved communities on the Upper East…